Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA

Medicure Q2 2020 Results and Conference Call Dates

WINNIPEG, MB, Aug. 5, 2020 /CNW/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, will release financial results for the quarter ended June 30, 2020 on Tuesday, August 11, 2020. The second quarter financial statements will be made available on the Company's website at www.medicure.com. Medicure will hold a conference call and webcast regarding the results on Wednesday, August 12, 2020 at 7:30 AM Central Time (8:30 AM Eastern Time).

Conference Call Info:

Topic:  Medicure's Q2 2020 Results

Call date:  Wednesday, August 12, 2020

Time:  7:30 AM Central Time (8:30 AM Eastern Time)

Canada toll: 1 (416) 764-8659

North American toll-free:  1 (888) 664-6392

Passcode:  not required

Webcast:    This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors   

You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT® (tirofiban hydrochloride) injection and ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com.

To be added to Medicure's e-mail list, please visit:        

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Medicure Inc.

These press releases may also interest you

at 03:10
"Mild cognitive impairment" (MCI) is the new frontline in the battle against Alzheimer's disease (AD), says Leslie Norins, M.D., Ph.D. CEO of MCI911.com, a new information service and clearinghouse. He advises, "Start counterattacking immediately...

at 03:05
WISE Srl, a medical device company developing next-generation implantable leads for neuromonitoring, neuromodulation and brain-machine interfacing, today announced the closing of a EUR 15 million Series C financing round. New investors, led by CDP...

at 03:05
Enesi Pharma ("Enesi"), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, is delighted to announce that ImplaVax® has...

at 03:05
Warriors Heart's private residential treatment program for "warriors" announces the purchase of the Bandera Lodge as part of their expansion and continued commitment to healing our frontline protectors. This newly acquired property will become the...

at 03:00
Innovative Gx Laboratories, a Texas-based molecular diagnostic company, is announcing the grand opening of its central testing laboratory in San Antonio, Texas, on Oct. 1, 2020. Innovative Gx specializes in molecular diagnosis using real-time RT PCR...

at 03:00
Adapting to the present COVID crisis, this year the 2020 Outsourcing in Clinical Trials USA Conference, one of several international clinical trials supply trade conferences organized by Arena International Events Group each year, adopted a virtual...

News published on 5 august 2020 at 12:02 and distributed by: